Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15655665 | 1.00 | USP2 (0.54) | USP2SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL22167903 | 0.88 | USP2 (0.51) | USP2SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL59641 | 0.88 | USP2 (0.54) | USP2SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL194709 | 0.88 | USP2 (0.54) | USP2SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL194710 | 0.88 | USP2 (0.54) | USP2SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL31126145 | 0.86 | USP2 (0.53) | USP2SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL27985533 | 0.86 | USP2 (0.53) | USP2SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL27130102 | 0.86 | USP2 (0.53) | USP2SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL1439935 | 0.85 | PDK1 (0.59) | USP2SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL25630738 | 0.85 | PDK1 (0.59) | USP2SMN1; SMN2RECQLMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2025201477-A1 | SPIROCYCLIC GSDME INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO.,LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-12319679-B2 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20150011546-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
| US-20150011546-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
| EP-2812001-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-05-01 | — | — | US | disclosed |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-05-01 | — | — | US | disclosed |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-05-01 | — | — | US | disclosed |
| WO-2013120104-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2012167733-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-12-13 | — | — | WO | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | USP2 3635/4885SMN1; SMN2 3059/4885RECQL 90/4885 |
| US-12319679-B2 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MAN2A1, MAN2B2, MGAT3 | USP2 3321/4885SMN1; SMN2 3045/4885RECQL 2016/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | USP2 3246/4885SMN1; SMN2 1780/4885RECQL 721/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | USP2 3635/4885SMN1; SMN2 3059/4885RECQL 90/4885 |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | USP2 3635/4885SMN1; SMN2 3059/4885RECQL 90/4885 |
| US-20150011546-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | USP2 420/4885SMN1; SMN2 3191/4885RECQL 1840/4885 |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | SYK, BTK, LYN | USP2 2919/4885SMN1; SMN2 3173/4885RECQL 1121/4885 |
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | USP2 2116/4885SMN1; SMN2 4767/4885RECQL 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.